API | larazotide acetate

larazotide acetate Report issue

Biologics Peptide Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Larazotide is a synthetic eight amino acid peptide that functions as a tight junction regulator and reverses leaky junctions to their normally closed state. It is being studied in people with celiac disease. ^Wikipedia

Chemistry

SMILES: CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C
InChIKey: NYGCNONRVCGHAT-UFIKZEAMSA-N
Mol. Mass: 785.9
ALogP: -3.18 Partition coefficient
ChEMBL Molecule:
larazotide acetate

More Chemistry

Pharmacology

Mechanisms of Action:
- Neuronal acetylcholine receptor subunit alpha-3 (Homo sapiens) ^UniProt
- Neuronal acetylcholine receptor subunit beta-4 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

at1001 | at-1001 | larazotide acetate | zot protein, vibrio cholerae (288-293)

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Celiac Disease (Phase 2)

COVID-19 (Phase 2)

Healthy Volunteers (Phase 1)

Inflammation (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 8
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue